Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 16/20 | 0.80 |
| ▸ | CTSB | P07858 | 10/20 | 0.80 |
| ▸ | CTSK | P43235 | 8/20 | 0.80 |
| ▸ | CTSS | P25774 | 7/20 | 0.80 |
| ▸ | CTSF | Q9UBX1 | 7/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15258029 | 1.00 | CTSL (0.80) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL3769844 | 0.89 | CTSL (0.84) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL13057625 | 0.89 | CTSL (0.84) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL4426232 | 0.89 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL12999157 | 0.88 | CTSL (0.71) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL3769856 | 0.88 | CTSL (0.71) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL4433974 | 0.83 | CTSL (0.79) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL2129239 | 0.82 | CTSL (0.79) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL3769857 | 0.82 | CTSL (0.62) | CTSLCTSBCTSKCTSSCTSF | |
| SCHEMBL3771497 | 0.82 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642799-B2 | Cysteine protease inhibitors for the treatment of parasitic diseases | MERCK CANADA INC. (CA) | 2014-02-04 | — | — | US | disclosed |
| US-8642799-B2 | Cysteine protease inhibitors for the treatment of parasitic diseases | MERCK CANADA INC. (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | MERCK FROSST CANADA LTD. (CA) | 2010-12-02 | — | — | US | disclosed |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | MERCK FROSST CANADA LTD. (CA) | 2010-12-02 | — | — | US | disclosed |
| WO-2009067797-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | CTSL, SERPINB1, CTSZ | CTSL 1/4885CTSB 24/4885CTSK 46/4885 |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | CTSL, SERPINB1, CTSZ | CTSL 1/4885CTSB 35/4885CTSK 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.